A purple and pink letter v on a white background.
April 10, 2025

Boost Semaglutide Results at Your Clinic With Venus Bliss MAX

Semaglutide and other GLP-1 receptor agonists have transformed the landscape of medical weight loss, allowing patients to shed significant weight in a short amount of time by regulating appetite and metabolism. However, weight loss alone does not always lead to the sculpted, toned appearance many patients desire. Rapid fat loss can leave behind stubborn fat deposits, sagging skin, and even loss of muscle tone, affecting patient satisfaction with their Semaglutide results.


For clinics offering GLP-1 treatments, integrating complementary aesthetic solutions can bridge the gap between weight loss and body transformation.
Venus Bliss MAX™ is a promising solution. This non-invasive body contouring system offers fat reduction, skin and cellulite treatments, and muscle toning to enhance the effects of Semaglutide, helping patients achieve a sculpted look.


Speak to an expert today to discover how Venus Bliss MAX™ can enhance your patients' Semaglutide results with fat reduction, skin and cellulite treatments, and muscle toning. 


The Role of Semaglutide in Medical Weight Loss


Semaglutide belongs to a class of medications known as GLP-1 receptor agonists. They work by mimicking a natural hormone involved in regulating blood sugar and hunger signals. As a result, this medication helps control food intake by reducing appetite, slowing gastric emptying, and improving insulin function. This results in significant and sustained weight loss for many individuals.


However, while Semaglutide effectively helps patients lose weight, it does not specifically target fat loss in certain areas, prevent muscle loss, or address skin laxity and cellulite.


After rapid weight loss, patients often experience concerns such as:


  • Loose and Sagging Skin: The skin loses its elasticity over time, and rapid weight loss does not allow it to retract fully.
  • Stubborn Fat Deposits: Even after substantial weight loss, some fat pockets may remain in areas like the abdomen, thighs, or arms.
  • Reduced Muscle Tone: Losing weight can also lead to muscle loss, especially if patients are not engaging in strength training.


For many patients, these challenges prevent them from thoroughly enjoying the GLP 1 results of their weight loss journey. While lifestyle changes can help, non-invasive aesthetic treatments offer a faster, more effective way to refine the body with no downtime.


Why Aesthetic Treatments Matter for Post-Weight Loss Patients


Patients invest a lot of effort into their weight loss journey, and their expectations go beyond just a number on the scale. They want aesthetic improvements; a toned body and smooth silhouette that reflects their hard work.


Venus Bliss MAX™ is a non-invasive body contouring machine that directly addresses these concerns, helping patients achieve the Semaglutied results they envision post-weight loss.


How Venus Bliss MAX™ Complements Semaglutide


Venus Bliss MAX™ is a powerful 3-in-1 body shaping platform designed to target the three most common concerns after weight loss: excess fat, skin laxity, and muscle tone loss. Each treatment is safe for all skin types and requires no downtime.


Fat Reduction With Laser Technology


Even though Semaglutide reduces overall body fat, some areas may still retain stubborn fat deposits. Venus Bliss MAX™ is a body contouring machine that uses a 1064 nm diode laser to target and destroy fat cells in problem areas like the abdomen, flanks, back, and thighs. The body naturally eliminates the destroyed fat cells, resulting in permanent fat reduction.


Skin and Cellulite Treatments With Multi-Polar Radio Frequency


Venus Bliss MAX™ features (MP)² technology, which combines Multi-Polar Radio Frequency (RF) and Pulsed Electro Magnetic Fields (PEMF) to stimulate collagen production and improve skin elasticity. This addresses sagging skin and cellulite, helping patients achieve a firmer, smoother appearance without surgery.


Muscle Toning With EMS Technology


Weight loss does not guarantee a toned body. Venus Bliss MAX™ includes FlexMAX EMS (Electrical Muscle Stimulation) technology, which induces powerful muscle contractions to strengthen and sculpt muscles in eight muscle groups, including the abdomen, buttocks, thighs, and arms. This improves body contours and helps with long-term weight maintenance by boosting muscle metabolism.


How Clinics Can Benefit From Integrating Venus Bliss MAX™


For clinics offering medical weight loss programs, adding Venus Bliss MAX™ provides significant business advantages:


  • Increased Patient Satisfaction: Patients undergoing both Semaglutide treatments and Venus Bliss MAX™ sessions see dramatic improvements in weight loss and body contouring. This leads to better patient retention and referrals.
  • A Unique Competitive Edge: Offering medical weight loss and a non-invasive body contouring system sets your clinic apart from competitors for total body transformation.
  • Higher Revenue Potential: Venus Bliss MAX™ is a body contouring machine that can be a profitable add-on service that appeals to a wide range of patients, including those not on Semaglutide but seeking non-invasive body contouring.
  • Non-Invasive, No Downtime: Unlike surgical options such as liposuction or tummy tucks, Venus Bliss MAX™ requires no downtime, making this body treatment an attractive choice for busy patients.


Transform Your Patients' GLP 1 Results With Venus Bliss MAX™


Adding Venus Bliss MAX™ to your clinic's weight loss offerings allows you to provide a complete transformation solution for your patients. With fat reduction, skin and cellulite treatments, and muscle toning in one non-invasive treatment, your patients can achieve weight loss and
toned muscles that reflect their hard work.


Enhance your Semaglutide patient care plans today.  Contact us to learn how  Venus Bliss MAX™ can take your clinic's offerings to the next level!


September 9, 2026
TORONTO, September 9 th , 2026 (GLOBE NEWSWIRE) – Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the appointment of Brad Oliver as Chief Executive Officer, effective as of September 7, 2026. He succeeds Rajiv De Silva, who will assume the role of Special Advisor to support a seamless leadership transition. The Board believes that Brad’s commercial leadership experience, strategic vision, and industry expertise position the Company well for its next phase of growth and value creation. Brad brings more than 20 years of leadership experience in the aesthetic industry, most recently as President & General Manager – Americas at Lumenis, and has a proven track record of driving growth globally, operational excellence, and innovation. "I am honored to be appointed Chief Executive Officer of Venus Concept and grateful for the confidence the Board has placed in me,” said Mr. Oliver. “The Company has established a strong foundation under Rajiv's leadership, and I look forward to working closely with him during the transition. Together with our employees, customers, and partners, we will remain focused on disciplined commercial execution, product innovation, profitable growth, and creating long-term value for our customers, employees, and shareholders.” “It has been a pleasure to lead Venus through a transformational time in the organization’s journey,” said Mr. De Silva. “I am grateful for the opportunity to work together with the leadership team, the Board and our partners to grow the business. We have transformed the commercial, operational and financial capabilities of the organization and built a strong foundation for the future. I remain highly confident in the Company’s strategy, pipeline and long-term growth opportunities. I look forward to supporting a smooth transition and watching Venus continue its transformation under Brad’s new leadership.” The Board expresses its gratitude to Rajiv for his leadership and ongoing commitment to the Company. As Special Advisor, Rajiv will work closely with Brad during the transition period to ensure continuity across strategic, operational, and customer-facing initiatives. “On behalf of the Board, I would like to thank Rajiv for his leadership and contributions to the Company and for his support during this transition to ensure a seamless handoff of leadership responsibilities,” said Avinash Amin, M.D., Managing Partner of Madryn Asset Management and Chairman of the Board. “The Board looks forward to Brad’s new leadership of the organization and is confident that his expertise will accelerate commercial efforts globally and the execution of its strategic priorities as the company progresses towards continuing to establish a leadership position in the Medical Device Aesthetics industry.” The leadership transition is not expected to impact the Company’s strategic priorities, customer relationships, employee commitments, or ongoing business operations. Venus Concept remains focused on delivering innovative solutions to its customers, expanding market opportunities, and driving sustainable long-term growth. About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft ® and the ARTAS iX ® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. View Full Article Investor Relations Contact : Damian Yeung, CPA investorrelations@venus.ai
By Yoni Nowmalki July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.